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Cloning and analysis of human papillomavirus type 18 codon optimized Flag-tagged E2 
protein 
Human papillomaviruses (HPVs) are highly prevalent pathogens, which are associated with 
wide variety of disorders. HPVs encode nine proteins. E2 protein is a key regulator of HPV 
life cycle. The E2 proteins function in initiation of DNA replication, transcriptional regulation 
and partitioning of viral genome. However, E2 proteins are expressed at very low level, which 
significantly complicates studies of these proteins. In order to increase expression of HPV18 
E2 protein, codon optimized sequence of E2 was inserted to the pCMV-Flag-4 vector, which 
contains Flag epitope. Flag-tag potentially may influence E2 protein properties and expression 
level. Results have shown that codon optimization of E2 protein encoding sequence increased 
the expression level of HPV18 E2 proteins in 293FT cells; codon optimized E2-Flag protein 
supported replication of HPV18 E2- deficient genome in U2OS cells. New HPV18 
E2c.o.pCMV-Flag construct is functional. 
KEYWORDS: HPV, papillomavirus, E2, replication, expression 
CERCS: B230 Mikrobioloogia, bakterioloogia, viroloogia, mükoloogia 
 
Inimese papilloomiviiruse tüüp 18 koodon optimiseeritud Flag-märgisega E2 valgu 
kloneerimine ja analüüs 
Inimese papilloomiviirused on väga levinud patogeenid mis on seotud paljude erinevate 
haigustega. HPVd kodeerivad 9 valku. E2 valk on HPV elutsükli võtmeregulaator. E2 valgud 
reguleerivad viiruse DNA replikatsiooni, transkriptsiooni ja viiruse genoomi jaotust 
tütarrakkude vahel. Kuid E2 valke ekspresseeritakse väga madalal tasemel, mis oluliselt 
raskendab nende valkude uurimist. E2 valgu ekspressiooni suurendamiseks sisestati koodon-
optimeeritud järjestus pCMV-Flag-4 vektorisse, mis sisaldab Flag epitoopi. Flag- märgis võib 
potentsiaalselt mõjutada valgu omadusi ja ekspressioonitaset. Tulemused näitasid, et E2 valgu 
koodoni optimeerimine suurendas HPV18 E2 valkude ekspressioonitaset 293FT rakkudes; 
koodon-optimeeritud E2-Flag valk toetas replikatsiooni HPV18 E2- puudulikus genoomis 
U2OS rakkudes. Uus HPV18 E2c.o.pCMV-Flag konstrukt on funktsionaalne. 
Märksõnad: HPV, papilloomiviirus, E2, replikatsioon, ekspressioon 
CERCS: B230 Microbiology, bacteriology, virology, mycology 
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LIST OF ABBREVIATIONS 
 
BPV – bovine papillomavirus 
BS – binding site 
C-terminal – carboxyl-terminal 
DBD – DNA binding domain 
dNTP – deoxynucleotide triphosphate 
dsDNA – double-stranded DNA 
GFP – green fluorescent protein 
HPV – human papillomavirus 
LCR – long control region 
MHC – major histocompatibility complex 
N-terminal – amino-terminal 
ORF – open reading frame 
TBP – TATA binding protein 
URR – upstream regulatory region 
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INTRODUCTION 
 
Human papillomaviruses (HPVs) are highly prevalent pathogens with great medical 
importance due to their association with several types of human cancer. HPVs are the most 
common sexually transmitted pathogens. They can be spread between partners from the skin 
and mucous membranes. Sexually transmitted HPV types are divided into two categories: 
“high-risk”, which can cause cancer, and “low-risk”, which can cause skin warts. HPV causes 
majority of cervical cancer among women, but also can be a reason of other anogenital and 
head and neck cancers (zur Hausen., 2009). Some specific types have been linked to 
cutaneous cancers. In fact, all cases of cervical cancer are caused by HPV. Constant research 
has increased the understanding of biology and host responses to HPV in molecular details. 
More precise understanding of HPV life cycle enables creating of virus-specific treatment. 
Currently the only way to prevent HPV infection is vaccination. 
Papillomaviruses infect epithelial cells of skin or mucosa in wide variety of vertebrates and 
induce cell proliferation. The viral genome is maintained as a circular dsDNA 
extrachromosomal replicating element within these cells (McBride., 2008). There are three 
modes of replication of papillomaviruses. The first one is establishment phase, which occurs 
upon the entry, when the viral genome is amplified to a low copy number. The second, 
maintenance phase, takes place when the viral genome replicates at a constant copy number 
synchronously with the cellular DNA in dividing cells, partitioning its genome between 
daughter cells. In the third, vegetative replication phase, the viral DNA is amplified to a high 
copy number in differentiated cells. This is followed by the packaging of genomes into the 
capsids (McBride., 2008). 
Papillomaviruses produce approximately nine proteins. Seven of them are expressed in the 
early stages of infection and two of them in the late stages. One of the best studied proteins is 
E2 early protein, which is the regulator of papillomavirus life cycle. E2 has also shorter 
forms, which are the products of alternative splicing 
Together with second early protein E1, E2 supports papillomavirus DNA replication, all other 
essential proteins and enzymes, which are needed for replication are provided by the host cell. 
The viral E1 protein acts together with E2 initiating viral replication. Moreover, E2 is needed 
for proper partitioning of viral genome in dividing cells in order to establish persistent 
infection. In addition, E2 can regulate the transcription of the viral genes. Thus, E2 serves as a 
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very important protein in PVs life cycle. Generally, research of E2 is challenging issue 
because of it very low expression level in host cells. 
The first part of the thesis gives a theoretical overview on papillomavirus life cycle and E2 
protein structure and function. The practical part aims at cloning of codon optimized sequence 
coding for E2 protein of HPV18 and subsequent testing of its expression level and biological 
activities. 
Present thesis was made in the Tartu University Institute of Technology in the Papillomavirus 
research group. 
  
 
7 
 
1. LITERATURE REVIEW 
 
1.1 Papillomaviruses - an overview 
 
Papillomaviruses are small, non-enveloped, double-stranded DNA viruses that belong to the 
Papillomaviridae family and infect the basal cells in epithelial tissue of a wide variety of 
animals. There are five major known HPV genera: α-papillomavirus, β- papillomavirus, γ-
papillomavirus, mu-papillomavirus and nu-papillomavirus, 49 species and over 200 types. 
The taxonomic classification of HPVs is based on the nucleotide sequence of the L1 gene, 
which encodes capsid protein (Bzhalava et al., 2015). 
Papillomaviruses infect keratinocytes in the basal layers of a stratified squamous epithelium 
(Zheng and Baker., 2006.) and cause wide range of diseases in their host: from benign tumors 
(warts, papillomas) to malignancies (de Villiers et al.,2004). HPV types of α-papillomavirus 
genera are known as a major cause of cervical cancer (Walboomers et al., 1999). These 
viruses are classified into high-risk or “oncogenic” (HPV16, HPV18), which immortalize 
human keratinocytes, causing cervical and anal cancer (de Villiers et al.,2004; Munoz et al., 
2003) and low-risk or “non-oncogenic” (HPV6, HPV11), which can may cause warts (Lacey, 
2005) and are very rarely found in genital malignancies (Zheng and Baker., 2006.). 
Human papillomavirus (HPV) is among the most common sexually transmitted infections 
worldwide and is associated with 95% of cervical cancer. (Health Canada. Human 
papillomavirus (HPV) (http://www.hc-sc.gc.ca/ hl-vs/alt_formats/pdf/iyh-vsv/diseases-
maladies/hpv-vph-eng.pdf; Munoz et al., 2003). This knowledge has led to development of 
vaccines, screening strategies and HPV testing (Cuschieri and Cubie, 2005). At the present 
time, there is no cure for HPV infection and prevention through vaccination is essential step 
for reducing of HPV-related disease. Available preventative vaccines are based on virus-like-
particles (VLPs) containing only of L1 major capsid protein which has an ability to assemble 
into VLPs. Gardasil, the quadrivalent HPV 6, 11, 16 and 18 recombinant VLP vaccine 
(4vHPV) is designed by Merck. The vaccine protects against HPV 16 and HPV18 that cause 
approximately 70% of cervical cancers and HPV 6 and 11 that cause 90% of genital warts. 
Another licensed vaccine is bivalent HPV 16 and 18 VLP, Cervarix (2vHPV) developed by 
GlaxoSmithKline. The nine-valent HPV VLP vaccine (9vHPV), Gardasil 9, which is the 
second generation HPV vaccine, contains HPV31, 33, 45, 52 and 58 VLPs connected with the 
quadrivalent VLP vaccine HPV types. Those vaccines were expanded to include males and 
were licensed in 2014 (Bryan et al., 2016). 
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1.2 Life cycle of papillomaviruses 
 
Human papillomaviruses usually invade through the skin damages and infect basal epithelial 
cells, which is the only epithelium cell layer that divides constantly. Gene expression and 
replication is closely associated with keratinocyte differentiation of the host (Figure 1.). To 
start infection, virus must reach basal cells and bind to cellular receptors. Virions initially 
attach to the heparan sulfate proteoglycan (HSPG) on the basal membrane, and transfer to the 
receptor expressed on the keratinocytes. (Kines et al., 2009). After the entry and uncoating, 
viral genomic DNA is transported to the nucleus, where it is maintained at a low-copy number 
as extrachromosomal element or episome (Moody and Laimins, 2010). HPV genome is small 
and does not encode polymerase, which is necessary for virus replication. Therefore, HPV 
requires DNA replication machinery of the host (Münger et al., 2004). The cell division of the 
host is necessary for viral DNA replication. E6 and E7 are expressed in the lower epithelial 
layers and drive cells to S-phase, which conduce to viral genome replication and cell 
proliferation (Doorbar, 2005). E6 and E7 inactivate p53 and retinoblastoma (pRB) tumor 
suppressors, maintaining the cell DNA replication potential (Münger et al., 2004). 
Papillomavirus replication and assembly takes place exclusively in the nucleus (Zheng and 
Baker, 2006). HPV amplification occurs in differentiating keratinocytes. With division of 
infected basal cell, viral DNA is distributed between both daughter cells: one of daughter cells 
migrates from basal layer to granular layer and initiates a program of differentiation. The 
other daughter cell keeps dividing in the basal layer, providing a storage of infected cells 
(Münger et al., 2004). Once genome amplification has been completed, the synthesis of the 
capsid proteins in upper layer of infected tissue is started (Doorbar, 2005). The capsid 
proteins L1 and L2 are required for viral packaging. This is followed by virion assembly and 
external release with peeled keratinocytes (Kajitani et al., 2012). 
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Figure 1. Stratified squamous epithelium and viral gene expression during the life cycle of 
the papillomavirus. (Moody and Laimins, 2010). 
 
1.3 Genome organization and proteins of papillomaviruses 
 
All papillomaviruses have circular double-stranded DNA that is approximately 8000 bp in 
size. The genome is divided into three major regions: early, late and long control region (LCR 
or Upstream Regulatory Region (URR). Six open reading frames (ORFs) in the early genome 
region encode the E1, E2, E4, E5, E6, E7 and E8 proteins, which are expressed in the lower 
layers at different stages during epithelium cells differentiation. The late region encodes L1 
and L2 capsid proteins, which are expressed in the upper epithelial layers (Zheng and Baker., 
2006.). LCR is does not encode any proteins but contains important elements such as 
replication origin, promoters and binding sites for viral E1 and E2 proteins and cellular 
transcription factors (McBride, 2008) 
E1 is the primary replication protein that binds specifically to the origin and initiates 
replication. E1 has ATPase and helicase activity, although the interaction with E2 is required 
for binding to ori site and initiation of viral DNA replication. After loading, E2 dissociates 
from the origin, E1 converts into double-helix hexameric ring and unwinds the viral 
replication origin to allow access of the cellular replication proteins. (McBride, 2008) 
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E2 protein plays a crucial role in viral genome transcription, replication and maintenance 
during cell division. The structure and role of the E2 protein is described in more details in the 
next chapter. 
E4 protein is an E1^E4 splicing product and is synthesized at very upper levels in the 
differentiated layers of the papillomavirus infection site, when the vegetative viral genome 
amplification begins (Davy et al., 2004). The E4 ORF region is located in E2 gene. Due to its 
abundant expression in late stages, it may serve as a biomarker of active virus infection 
(Middleton et al., 2003). E4 associates with keratin filaments that disrupt the stability of 
keratin networks and leads to particle release from the cell (Davy et al., 2004). 
E5 is short, membrane-associated, hydrophobic protein. (Schlegel et al., 1986). BPV1 E5 is 
located in the membranes of the endoplasmic reticulum and Golgi apparatus of transformed 
cells as a dimer (Horwitz et al., 1988). E5 proteins affect activity of growth factor receptors 
by acidification of Golgi apparatus, which contributes to cell transformation, stimulate the 
proliferation of infected basal cells (DiMaio and Mattoon, 2001) and protect host cells from 
apoptosis (Hu et al., 2010). Also, E5 downregulates surface expression of major 
histocompatibility complex (MHC) class I molecules, helping the virus to evade the host 
immune system (Ashrafi et al., 2006; Zhang et al., 2003). 
E6 and E7 proteins are powerful oncoproteins. They both are sufficient for the efficient 
immortalization of primary human squamous epithelial cells (Münger et al., 1989). E6 and E7 
both interact with tumor suppressor gene products. The E6 protein associates with p53, which 
leads to degradation of p53 tumor suppressor through the ubiquitin-dependent proteolysis 
system. This prevents p53 from inducing apoptosis of abnormal cells, which contributes to 
tumorigenesis (Huibregtse et al., 1991). The E6 proteins from high-risk HPV types have 
higher affinity for p53, than low-risk HPV types (Li and Coffino, 1996). 
E7 protein is a major HPV oncoprotein, and E7 expression in high-risk HPVs is essential for 
both cell transformation and viral pathogenesis. E7s’ main target is retinoblastoma (Rb) tumor 
suppressor and its related proteins including p107 and p130 (Garnett and Duerksen-Hughes, 
2006). E7 proteins destabilize pRB through ubiquitin-proteasome-mediated proteolysis 
(Boyer et al., 1996). In addition, interaction between pRB and E7 proteins results in the 
release of E2F family of transcription factors. This leads to activation of genes necessary for 
cell S-phase entry and progression (McLaughlin-Drubin and Münger, 2009). Same as E6 
proteins, the E7 proteins of high-risk HPV types bind pRb with higher efficiency compared to 
low-risk E7 (Münger et al., 1989). 
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All papillomaviruses encode an E8^E2 repressor proteins, which consist of a short E8 peptide 
fused to the entire hinge and DNA binding domains of E2. These proteins are powerful 
repressors of viral transcription and replication (Zobel et al., 2003; Stubenrauch et al., 2001) 
L1 and L2 are papillomavirus structural proteins and are essential for DNA packaging. The 
expression and assembly of infectious virions occurs in terminally differentiated layers of 
epithelial tissues. L1 is major protein and can efficiently self-assemble into virus-like particles 
(Kirnbauer et al., 1992; Kirnbauer et al., 1993). L2 is a minor protein and is required for 
efficient encapsidation of HPV DNA during the late phase of infection (Zhao et al., 1998). 
 
Figure 2. Schematic representation of papillomavirus genome. Open reading frames (ORFs) 
are shown as grey arrows. The upstream regulatory region (URR) is marked as a black line. 
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1.5 Papillomavirus E2 protein 
 
1.5.1 E2 protein - an overview 
All papillomaviruses encode E2 protein, which is an essential regulatory protein. E2 protein is 
multifunctional and involved in many processes in the viral life cycle, such as replication, 
transcription and maintenance of the viral genome. E2 is expressed at establishment and 
maintenance phases of the viral life cycle and known as E2-TA or E2 transactivator 
(McBride, 2013). 
The full-length E2 protein is expressed from the entire open reading frame (ORF). E2 protein 
consists of a conserved N-terminal transactivation domain of about 200 amino acids long and 
C-terminal binding domain of about 100 amino acids long. (McBride et al., 1989b). N-
terminus is necessary for replication, transcriptional activation and repression, interaction 
with the E1 protein, as well as many cellular factors. C-terminal domain has sequence specific 
DNA and dimerization properties (McBride and Myers, 1997). The linker sequence provides 
a flexible connection between two domains, which varies among the papillomavirus genera by 
length and sequence (McBride et al., 1989b). 
Besides full-length E2 protein, all papillomaviruses have a potential to encode shorter forms 
of E2 that contain C-terminal domain. These proteins have been alternatively named E8^E2, 
E8^E2C, E1^E2, E1M^E2 and E9^E2. The shorter forms of E2 serve as repressors of viral 
replication and transcription. Elimination of E8^E2 expression leads to over-replication of 
HPV genomes (McBride, 2013). 
 
1.6 E2 functions 
 
1.6.1 Transcription 
 
The E2 proteins are the main transcriptional regulators of papillomaviruses (Lambert et al., 
1987). E2 regulates the viral transcription through binding as a dimer to its specific 
recognition sites. The binding sites for E2 protein are located within URR region and are 
highly conserved. The URR in HPVs most often contains 4 binding sites (Spalholz et al., 
1985) and the sites with the highest affinity have the sequence ACC(N)4GGT (Androphy et 
al., 1987; Li et al., 1989). E2 also uses non-consensus binding sites with lower affinity 
(Newhouse and Silverstein, 2001), such as AAC(N)6GGT or AAC(N)6GTT in BPV1 (Li et 
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al., 1989). The E2 protein activates or represses the viral transcription, depending on the 
context of binding sites and nature of the associated cellular factors, which virus recruits. E2 
binding sterically hinders the binding of cellular factors such as Sp1 and TBP (TATA binding 
protein) to proximal promoter elements in the viral genome (Dostatni et al., 1991; Romanczuk 
et al., 1990; Tan et al., 1994) and prevents the formation of the transcriptional initiation 
complex, which leads to transcriptional repression of the early promoter (Thierry, 2009). 
In many viruses, the full-length E2 protein can either activate or repress viral transcription in 
dose-dependent manner (Bouvard et al., 1994; Fujii et al., 2001; Steger and Corbach, 1997; 
Thierry and Yaniv, 1987). Studies have shown, that the HPV18 early promoter P105 is 
activated in the presence of low E2 amounts and repressed, when the E2 concentration is 
increased. E2 binds with highest affinity to the most distal E2 binding site 4 (BS-4) and can 
upregulate viral early gene expression. The early promoter is activated in the presence of low 
concentrations of E2, when it binds BS-4. As E2 concentration rise, E2 occupies BS-2 and 
BS-1 with reduced affinity that are involved in transcriptional repression. (Steger and 
Corbach, 1997, Demeret et al., 1997). This dose-dependent sequence of DNA binding events 
correlates with an increasing the expression of E1, E2, E6 and E7 (Demeret et al., 1997) 
The shorter forms of E2 act as transcriptional repressor. Repression can be mediated by 
competition for binding to E2 binding sites (Lambert et al., 1987) or by binding the repressor 
complexes to viral DNA with the help of the E8-derived peptide. (Ammermann et al., 2008; 
Fertey et al., 2010; Powell et al., 2010). Dimerization of shorter forms of E2 with full-length 
E2 cam also repress transcriptional activation (Kurg et al., 2006). 
In HPV-associated cancers E2 is often disrupted, which negatively affects the E2-mediated 
repression and leads to increased expression of the E6 and E7 oncogenes. Also, high-levels of 
E2 can induce the expression of the late HPV genes L1 and L2, causing read-through at the 
early polyadenylation signal into the late region of HPV genome (Johansson et al., 2012). 
 
1.6.2 Initiation of viral DNA replication 
 
To initiate viral DNA replication, E2 must load the E1 protein, which serves as helicase, onto 
the replication ori, which contains an E1 binding site, an A/T regions and at least one E2 
binding site (Ustav et al., 1993; Ustav et al., 1991). The initiation of replication occurs in 
several steps: specific recognition of the origin precedes origin unwinding, helicase delivery 
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and possessive DNA synthesis. E2 is required to enhance and support the function if E1, the 
primary replication protein (Frattini and Laimins, 1994; Mohr et al., 1990). After loading, E1 
converts to a double-hexameric helicase to unwind the DNA, which is followed by E2 
dissociation from the complex (Sanders and Stenlund, 1998). Replication activity correlates 
very well with the formation of E1-E2-ori complex. Also, E2 protein determines the binding 
specificity of E1 helicase at the HPV origins. (Sedman and Stenlund. 1995). 
 
1.6.3 Genome maintenance 
 
In order to maintain the viral genome as an independent, episomal element, it has to be 
preserved and divided uniformly among daughter cells during mitosis. Virus association to 
cellular chromatin provides distribution of viral genomes to daughter cells in approximately 
equal numbers and ensures their retention in the nucleus after cell division. The partitioning 
and episomal maintenance of the viral genomes in the maintenance phase depends on the viral 
E2 protein (Ilves et al., 1999; Skiadopoulos and McBride, 1998). Long-term and stable 
maintenance of replicons requires, in addition, the minichromosome maintenance element, a 
cis element containing multiple E2 binding sites (Piirsoo et al., 1996). The E2 protein tethers 
the viral genome to the host mitotic chromosomes to ensure retention, maintenance and 
partitioning of the viral genome (Bastien and McBride, 2000; Ilves et al., 1999; Lehman and 
Botchan, 1998; Skiadopoulos and McBride, 1998). The DBD of E2 protein binds to binding 
sites in the viral genome and other regions of E2 (such as TA domain) tether the genome to 
the mitotic chromosome of the host through protein-protein interactions (McBride, 2013). 
However, studies have shown that E2 represses transcription by recruiting factors that 
manipulate cellular chromatin processes (Nishimura et al., 2000; Schweiger et al., 2007; 
Smith et al., 2010; Wu et al., 2006). Heterodimers, formed by long and short forms of E2, 
support the initiation of replication but are defective for partitioning (Kurg et al., 2006, 2009). 
 
1.7 Replication 
 
E2 is a multifunctional protein, which is involved in the viral genome replication. The first 
replication phase is initial amplification, during which the viral copy number is increased to a 
few hundred copies per cell to establish infection in dividing cells and occurs, when the viral 
particle enters cell. E1 and E2 are early viral proteins, which are essential for replication 
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initiation and elongation. All other proteins and enzymes, needed for replication, are provided 
by the host cell replication machinery. The second phase of PVs is stable maintenance 
replication, where the viral copy number is kept constant during several rounds of cell 
division (McBride, 2008). E2 distributes genomes between daughter cells by binding to the 
viral genome via its DBD domain and to the chromosomes via its TAD domain (Ilves et al., 
1999). The first and second phase take place in the basal cells in the bottom of the layer of 
epithelium. (McBride, 2008) 
The last stage of viral replication is vegetative replication, where viral genomes are amplified 
to a high number of copies. It occurs in the differentiated keratinocytes, when they move 
upward in the epidermal layer. The second round of amplification requires E1 and E2 
proteins. The abundant increase of E1 and E2 proteins is followed by the upregulation of the 
differentiation-dependent late promoter (Hummel et al., 1992; Ozbun and Meyers, 1998b). 
The E6 and E7 proteins are absolutely required for S-phase re-entry. Moreover, E7 protein is 
needed for G2-phase prolonging in differentiated cells (Banerjee et al., 2011), when 
vegetative amplification of HPV DNA takes place (Wang et al., 2009). There are two 
mechanisms suggested for vegetative replication. During differentiation, the cellular 
environment changes and cells no longer produce factors, which are necessary for DNA 
replication. That means that environment becomes unsuitable for DNA replication and the 
virus must overcome these restrictions. Rolling-circle replication is unidirectional and one 
initiation event generates multiple copies of the genome thereby enabling rapid synthesis of 
viral DNA. As theta mode of replication requires initiation with every round of replication, 
the virus can switch to rolling-circle replication mode, facilitating the generation of large 
amounts of DNA and escaping the unfavorable conditions of the differentiated cell (Flores 
and Lambert, 1997). After amplification phase, the viral genome is packaged into the capsids. 
(McBride., 2008). 
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2. EXPERIMENTAL PART 
 
2. Objective of the study 
 
E2 is a very important HPV protein. It plays a crucial role in the viral life cycle regulation. 
HPV E2 proteins are expressed at very low levels and generally it is very difficult to detect 
them using Western blot analysis (Kurg et al., 2010). This fact significantly complicates 
studies of these proteins. In order to increase their expression level, nucleotide sequence of 
the 5’ end of HPV18 E2 ORF was changed to have the most frequent codons in mammalian 
cells (Oliveria et al., 2006). To facilitate detection of the expression level of E2 protein, codon 
optimized E2 protein encoding sequence was cloned into pCMV-Flag-4 plasmid, which 
contains polypeptide protein tag DYKDDDDK, where D is aspartic acid, Y is tyrosine, and K 
is lysine. 
 
The objective of this study is: 
 
● cloning of codon optimized sequence coding for E2 protein of HPV18 into pCMV-
Flag-4 plasmid; 
● control of the expression level of the Flag-tagged E2 protein using Western blot 
analysis; 
● testing biological activity of the modified E2 protein using HPV18 genome deficient 
for E2 expression (HPV18E2-) and U2OS cells; 
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2.2 Materials and methods 
 
2.2.1 Plasmids 
 
● HPV18 E2 expression vector (pQM18E2) 
pQM18E2 vector comes from laboratory collection. This vector encodes codon optimized E2 
which biological activity has been tested previously (Kurg et al., 2010). 
● pJET1.2/blunt cloning vector 
2974 bp length cloning vector. It is suitable for cloning of PCR products and sequencing of 
cloned fragments (Thermo Fisher Scientific). 
● pCMV-Flag-4 vector 
6271 bp length vector (Sigma Aldrich). It contains HindIII and BamH restriction sites and 
Flag tag encoding sequence before the HindIII site. 
● E2-Flag HPV18 plasmid 
This plasmid comes from laboratory collection. It encodes Flag-tagged wild type E2 of 
HPV18 cloned in pCMV-Flag-4 vector in HindIII and BamHI restriction sites. 
● Wild type HPV18 minicircle 
This plasmid comes from laboratory collection and encodes wild type HPV18 genome. 
● HPV18E2- minicircle 
This plasmid comes from laboratory collection. It encodes HPV18 genome containing point 
mutation in E2 first AUG and therefore deficient for expression of E2 protein and replication. 
 
2.2.2 PCR and agarose gel electrophoresis 
 
Codon optimized E2 was amplified using PCR, pQM18E2 plasmid (Kurg et al., 2010) as a 
template and Eppendorf 5331 Mastercycler Gradient PCR Thermal Cycler. PCR mix included 
1μl of template DNA (20 ng/μl), 4μl of 5xbuffer, 0,5 μl of oligo mix (10 μM), 0,4 μl of dNTP 
(10mM), 0,2 μl of Phusion Polymerase (Thermo Fisher Scientific) and 14,9 μl of H20. The 
following primers were used: 
HPV18 E2 RV BamHI          GGATCCTTACATTGTCATGTATCC 
HPV18 E2 FW HindIII         AAGCTTCAGACCCCCAAAGAGACC 
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PCR program consisted of 3 min 96 oC of initial denaturation of the template and 20 cycles of 
denaturation at 96 oC for 30 sec, primer annealing at 59 oC for 20 sec and synthesis of the 
product at 72 oC for 1 min. The samples were analyzed on 0,8% agarose gel in TAE buffer. 
 
2.2.3 Purification of PCR products from the gel 
 
Amplified codon optimized E2 DNA fragment was excised and purified from the agarose gel 
using Zymoclean™ Gel DNA Recovery kit (Zymo Research) according to manufacturer’s 
instructions. A piece of agarose gel was melt at 55 oC for 10 min, the suspension was 
transferred to column containing DNA binding silica. After the series of washes, DNA was 
eluted in 20 µl of nuclease-free water. 
 
2.2.4 Ligation of purified PCR products into pJET1.2/blunt cloning vector 
 
Ligation reaction contained 0,5 μl of pJET1.2/blunt cloning vector, 7,5 μl of the gel purified 
PCR product, 1 μl of 10x buffer, and 1 μl T4 ligase. Ligation mix was incubated at 16 ˚C 
overnight. 
 
2.2.5 Transformation of DH5a 
 
Eschericia coli DH5a competent cells were transformed with the ligation mix (pJET1.2/blunt 
+ purified codon optimized E2 PCR product) and plated on LB agar supplemented with 50 
µg/ml of ampicillin. Cells were incubated overnight at 37˚C. Only bacterial cells containing 
recombinant plasmids, were able to form colonies. Next, five colonies were selected and 
inoculated into LB supplemented with 200 µg/ml of ampicillin. Cells were grown at 37˚C 220 
rpm overnight. 
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2.2.6 Isolation of plasmid DNA (Miniprep) 
 
Plasmid DNA was isolated according to the protocol of FavorPrep™ Plasmid Extraction Mini 
Kit. Briefly, bacteria were lysed, DNA was bound to the silica matrix, washed and eluted in 
50 µl of nuclease-free water. Concentration of DNA was measured with NanoDrop™ 
spectrophotometer. 
2.2.7 Restriction analysis and sequencing 
 
Restriction reaction contained 0,5 μg DNA, 2 μl of 10xFastDigest buffer, 0,5 μl of HindIII 
enzyme, 0,5 μl of BamH enzyme and H20 (up to 20 μl). The reaction was incubated at 37˚C 
for 1 hour. To detect the presence of the correct bands, the samples were run on 0,8% agarose 
gel, and 1kB O’GeneRuler DNA ladder (Thermo Fisher Sientific) was used as a reference. 
The size of the expected fragments was 2,7 and 1,1 kb. 
 
In order to check the sequence of the cloned codon optimized E2, samples were sent to the  
Core Laboratory for DNA Genotyping and Sequencing in the Institute of Molecular and Cell 
Biology. Sequencing analysis did not reveal any mutation in E2. 
 
Next, coding sequence the codon optimized E2 was excised from pJET1.2/blunt vector, 
purified from agarose gel and ligated into the pre-cleaved and agarose gel-purified pCMV-
Flag-4 vector. Restriction reaction contained 5 μg DNA, 2 μl of 10xFastDigest buffer, 1,5 μl 
of HindIII enzyme, 1,5 μl of BamHI enzyme and H20 (up to 20 μl). Ligation reaction was 
performed as described in 2.2.4. The obtained construct was defined as HPV18 E2c.o.pCMV-
Flag. 
 
2.2.8 Cell lines and transfection of U2OS cells and 293T cells 
 
In my work, I used the human osteosarcoma U2OS cells and 293FT cells (a derivative of 
Human Embryonic Kidney cell line HEK293). U2OS cells were cultured in the IMDM 
(Iscove’s Modified Dulbecco’s Medium) + 10% Fetal Bovine Serum + 1% penicillin/ 
streptomycin mix. 293T cells were grown in DMEM-High Glycose (Dulbecco's Modified 
Eagle Medium) + 10% Fetal Bovine Serum + 1% penicillin/ streptomycin mix. Cells were 
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plated on 6-well plates 24 hours before transfection. Cells were incubated at 37˚C and 5% 
CO2. 
 
Transfection of U2OS cells 
U2OS cell were transfected using Reagent 007 (Icosagen). Different amounts of HPV18 
E2c.o.pCMV-Flag plasmid were added for each transfection: 0, 0,5 ng, 1 ng, 10 ng and 100 
ng. Also, 0,5 μg of mutant HPV18E2- genome was added to each sample. GFP-encoding 
plasmid (100 ng) was used as a control. Also, 200 ng of reference HVP18 wild type genome 
was transfected separately. The transfection mixes contained 20 μl of reagent 007 and 
respective DNA in sterile water. DNA/Reagent 007 mixture was incubated at room 
temperature for 5-10 min. Then, cells were washed with PBS and 1,5 ml of pure IMDM and 
DNA/007 mixture were added to each well. After 2-3 hours, normal growth medium (IMDM 
supplemented with FBS and ampicillin/streptomycin) was added to the cells, and cells were 
incubated for 72 h. 
 
Transfection of 293FT cells 
293FT cells were transfected using Polyethylenimine reagent (PEI) (Inbio). First, 100 μl of 
pure DMEM was added to each microtube. Different amounts of HPV18 E2c.o.pCMV-Flag 
plasmid were diluted in DMEM: 200 ng of HPV18 E2c.o.pCMV-Flag + 1800 ng empty 
vector, 1000 ng of HPV18 E2c.o.pCMV-Flag + 1000 ng empty vector and 2000 ng of 
E2c.o.pCMV-Flag. To compare expression of codon optimized and wild type E2, 2000 ng of 
plasmid encoding Flag-tagged wild type E2 of HPV18 was added to the separate microtube. 
Next, 10 μl of PEI stock solution (concentration 80 mg/ml) was diluted in 790 μl of sterile 
water (resulted concentration 1 mg/ml) and 5 μl of the diluted PEI were added to each 
microtube. DNA/PEI mixture was left at room temperature for 5-10 min. The cells were 
washed with PBS and 1,5 ml of pure DMEM and DNA/PEI mixes were added. After 2-3 
hours, 2 ml of normal growth medium (DMEM supplemented with FBS and antibiotics) was 
added to the cells, and cells were incubated for 48 h. 
 
 
 
21 
 
2.2.9 Replication assay using different concentrations of E2c.o.pCMV-Flag construct 
and HPV18E2- and HPV18wt genomes 
 
Total DNA from transfected U2OS cells was extracted as described in Ref. (Geimanen et al., 
2011). Five µg of total DNA was cut with restriction enzymes BglI (2 μl per sample), which 
linearizes HPV DNA, and DpnI (2 μl per sample), which cuts only bacterially methylated 
DNA. The products were run on 0,8% gel, 30 V, in TAE buffer overnight and then blotted to 
nylon membrane in 10x SSC buffer using capillary transfer method, which was followed by 
pre-hybridization in solution containing 9 ml 20x SSC, 3 ml 50x Denhardt’s Reagent (Termo 
Fisher Scientific), 1.5 ml 10% SDS, 0.6 ml of denaturated salmon sperm DNA and 16 ml of 
sterile water at 65 oC for 2 h and hybridization with a radioactively labelled HPV18 specific 
probe at 65 oC under slow rotation overnight. The probe was synthesized using 100 ng of 
linearized and gel-purified HPV18 template, α-32P-dCTP (PerkinElmer) and DecaLabel DNA 
Labeling Kit (Thermo Fisher Scientific) according to manufacturer’s instructions. After 
hybridization, the membrane was washed and exposed to X-ray film. 
 
2.2.10 Immunoblotting 
 
For immunoblotting analysis, transfected 293FT cells were lysed in 200 µl of RIPA buffer (50 
mM Tris pH 7,5, 150 mM NaCl, 2 mM EDTA, 0,1% SDS and 0,1% TRITON-X100) for 15 
min on ice. The lysates were cleared by centrifugation at 4 oC 13 000 rpm for 10 min. Next, 
15 µl of lysate was mixed with 15 µl of 2x Laemmli Sample Buffer (0.125M Tris-Cl, pH 6.8, 
4% SDS, 20% glycerol, 100 µM DDT, 0.004% bromophenol blue). Samples were denaturated 
at 100 oC for 10 min. Proteins were separated by polyacrylamide gel electrophoresis and 
transferred to PVDF membrane (Millipore). The membrane was blocked in PBS containing 
0,1 % Tween-20 and 5 % of non-fat dry milk and then incubated with anti-Flag-HRP antibody 
(Sigma Aldrich) diluted 1:5000 in PBS-Tween solution containing 2,5 % of non-fat dry milk 
at RT and slow end-to-end rotation for 1 hour 20 min. The membrane was washed in PBS-
Tween solution 3 times for 15 min. Enhanced chemiluminescence (ECL) HRP substrate 
(SuperSignal™ West Dura Extended Duration kit, Thermo Fisher Scientific) was added to 
membrane and incubated for 1 min at RT. The membrane was rinsed in PBS-Tween for 10 
sec and exposed to X-ray film. 
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2.3 Results and discussion 
 
In order to check, if E2-Flag codon optimized protein is functional, its biological activity must 
be tested. It is known that E2 (together with E1 protein) is absolutely needed for HPV 
replication. Namely, if virus genome enters the host cell, it can replicate its DNA and partition 
it to daughter cells only in the presence of E1 and E2 proteins. All other proteins, which are 
essential for viral genome replication are provided by the host cell replication machinery. 
Osteosarcoma U2OS cells support viral replication, i.e they have all vital proteins required for 
HPV replication, except E1 and E2, which are encoded by HPV genome. 
 
If wild type genome of HPV is transfected into U2OS cells, E1 and E2 are expressed and viral 
genome replication is initiated, and in three days the number of virus genomes in cells will 
dramatically increase. However, if HPV18E2- is transfected, it will not be able to replicate 
because of absence of E2, and after three days HPV18E2- DNA will be almost disappeared 
from the cells. In that case, cells will keep dividing, whereas mutant HPV genome will not 
partition between daughter cells and number of viral copies will decrease. However, if the 
plasmid, which encodes the functional protein E2 is added to the cells with mutant HPV 
genome, then this E2 compensates the absence of endogenous E2 and the mutant genome 
replicates. 
 
Both E1 and E2 are toxic for cells, i.e. cells can die, if those proteins are in abundance. In case 
of wild type virus, the amount of E1 and E2 proteins is regulated so, that those proteins are 
enough for the viral genome replication. If exogenic E2, which is expressed from plasmid is 
added to the cells, its amount is unclear. It can be very high, much higher than is case of wild 
type virus and endogenic E2. On the other hand, it can be too low, if less plasmid is added. 
Besides, introduction of exogenous sequences may alter biological activity of the resulted 
protein. The modified E2 protein cloned into pCMV-Flag vector contains N-terminal Flag tag 
that potentially may influence its properties and expression level. Therefore, different 
amounts of codon optimized E2 encoding plasmid have to be tested together with HPV18E2- 
genome. In this way, it is possible to understand, if new codon optimized E2-Flag protein has 
the same properties as wild type E2 and, which amount of plasmid has to be transfected to 
manifest these properties. 
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My work consisted of two parts. First, I generated a new construct by cloning codon 
optimized HPV18 E2 encoding sequence obtained by PCR into pCMV-Flag-4 expression 
vector. The obtained construct was defined as E2c.o.pCMV-Flag. Second, I tested the 
biological activity of the codon optimized Flag-tagged E2 protein using different 
concentrations of E2c.o.pCMV-Flag construct and HPV18E2- mutant with subsequent 
detection using Southern blot analysis. 
 
Cloning of E2c.o.pCMV-Flag 
 
In order to obtain the codon optimized HPV18 E2, I amplified the template described in Ref. 
(Kurg et al., 2010) using primers containing HindIII and BamHI sites on their 5’ ends. The 
obtained PCR product was purified and cloned into vector. Plasmid DNA of five independent 
clones of HPV18E2co-pJET1.2/blunt was extracted, and the clone lacking mutations was 
verified by restriction analysis and DNA sequencing using primers specific for pJET1.2/blunt 
vector. The correct fragment encoding codon optimized E2 was excised from pJET1.2/blunt 
vector and cloned into pCMV-Flag-4 vector between HindIII and BamHI sites. Plasmid DNA 
of 5 independent clones of the presumptive E2c.o.pCMV-Flag was purified (their 
concentrations are shown in Table 1) and controlled by restriction analysis using HindIII and 
BamHI enzymes (Figure 3). The length of the expected fragments was 6271 nt (corresponding 
to length of the pCMV-Flag-4 vector) and 1093 nt (corresponding to the length of HPV18 E2 
with additional HindIII and BamHI restriction sites on 5’ and 3’ ends, respectively). 
Table 1. The concentration of the obtained E2c.o.pCMV-Flag-4 plasmid DNA 
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 
215 ng/μl. 
 
127 ng/μl. 
 
185 ng/μl. 
 
189 ng/μl. 
 
229 ng/μl. 
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Figure 3. Restriction analysis of the E2c.o. cloned into the pCMV-Flag-4 cloning vector. Clones were 
cut using HindIII and BamHI restriction enzymes. Expected length of the fragments was 6271 nt 
(corresponds to pCMV-Flag-4 vector) and 1093 nt (corresponds to E2c.o. PCR product). DNA ladder 
O’GeneRuler 1kB was used as a reference. 
 
Control of expression level of codon optimized HPV18 E2 
 
In order to check, whether HPV18 codon optimized Flag-tagged E2 is expressed, I used 
293FT cells and subsequent Western blot analysis. HPV18 wild type Flag-tagged E2 was used 
as a control. 293FT cells were transfected with 200, 1000 or 2000 ng of E2c.o.pCMV-Flag 
encoding plasmid and 2000 ng of HPV18 wild type E2pCMV-Flag construct. The transfected 
cells were incubated for 48 h and lysed. Whole cell extracts were subjected to Western blot 
using anti-Flag-HRP antibody (Figure Y). As expected, the analysis revealed that Flag-tagged 
wt E2 was not detectable, but the Flag-tagged codon optimized E2 was detectable from the 
sample transfected with 2000 ng of E2c.o.pCMV-Flag encoding plasmid (Figure 4). The band 
was detected at approximately 42 kDa that corresponds to the expected size of HPV18 E2. 
Also, non-specific band at approximately 70 kDa was detected in all samples. 
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Figure 4. Detection of HPV18 codon optimized Flag-tagged E2 protein by Western blot. Different 
amounts of the constructs encoding HPV18 E2c.o.-Flag were transfected into 293FT cells. Samples 1 
and 3 also contained 1000 ng and 1800 ng of empty vector, respectively. The cells were lysed 48 h 
after transfection and subjected to WB analysis using anti-Flag-HRP antibody. Asterisk indicates non-
specific band. 
 
Control of biological activity of codon optimized Flag-tagged E2 in U2OS cells 
 
To check the biological activity of HPV18 codon optimized Flag-tagged E2, I used U2OS 
cells and analyzed results using Southern blot. Wild type HPV18 minicircle was used as a 
control. U2OS were transfected with HPV18 E2-genome and either with 0,5. 1, 10, 100 ng of 
E2c.o.pCMV-Flag encoding plasmid or 150 ng of GFP. Last transfection contained 200 ng of 
HPV18 wild type genome used as a control. Transfected cells were incubated for 72 hours 
and lysed. Results show that new E2c.o.pCMV-Flag plasmid supports viral DNA replication. 
Eight kb bands correspond to the size of replicated HPV18 DNA (Figure 5, lanes 2 – 5). 
Highest amount of replicated viral DNA is detected in the sample with 100 ng of 
E2c.o.pCMV-Flag plasmid (Figure 5, lane 5). 
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Figure 5. Analysis of E2 biological activity using Southern blot. HPV18E2- genome was transfected 
together with either different amounts of the construct encoding HPV18 E2c.o.-Flag (lanes 2 – 5) or 
GPF (lane 1). Wild type HPV18 genome was transfected as a control (lane 6). in U2OS cells, 72 h. 
The DpnI-resistant replicated HPV18 DNA was linearized using BglI restriction enzyme. It forms an 8 
kb band on the top of the gel. The DpnI-sensitive material (bacterially purified DNA used for 
transfection) forms a series of lower molecular weight bands. Linearized using BglI HPV18E2- 
plasmid (500 pg) used for transfection is shown in lane 7. 
  
 
27 
 
CONCLUSION 
 
Present study gives a theoretical overview on the HPV genome organization and life cycle, 
especially focusing on E2 proteins and their functions. 
Papillomavirus E2 protein is a multifunctional protein. E2 protein is a key regulator of HPV 
life cycle. Studies of E2 protein are complicated due to low protein expression levels. In order 
to increase expression of E2 protein, codon optimized sequence was inserted to the pCMV-
Flag-4 vector, which contains Flag- tag encoding sequence. Flag-tag potentially may 
influence E2 protein properties and expression level. 
The carried out experiments resulted in the following conclusions: 
● codon optimization of E2 protein sequence increased the expression level of HPV18 
E2 proteins in 293FT cells; 
● codon optimized E2-Flag protein supported replication of HPV18 E2- deficient 
genome in U2OS cells. 
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Inimese papilloomiviiruse tüüp 18 koodon optimiseeritud 
Flag-märgisega E2 valgu kloneerimine ja analüüs 
Kristina Orlova 
Resümee 
 
Inimese papilloomiviirused on väga levinud patogeenid, neil on suur meditsiiniline tähtsus, 
sest juba ammu on leitud nende seos halvaloomuliste kasvajatega. Seksuaalselt levivad tüübid 
jagunevad kahte kategooriasse: “kõrge riskiga”, mis võivad põhjustada vähki ja “madala 
riskiga”, mis võivad põhjustada tüükaid. Põhjalikum HPV uurimine on väga oluline, kuna 
HPV elutsüklist täpsem arusaamine võimaldab luua viirusvastast ravi. Tänapäeval on ainus 
võimalus HPV nakkuse ennetamiseks vaktsineerimine. 
Papilloomiviirused on väikesed DNA viirused, mis nakatavad epiteelrakke paljudel 
selgroogsetel ja indutseerivad rakkude proliferatsiooni. Viiruse genoomi säilitatakse sellistes 
rakkudes tsirkulaarse episomaalse replitseeruva elemendi kujul. 
Papilloomiviirused kodeerivad üheksa valku: E1, E2, E4, E5, E6, E7, E8, L1 ja L2. Kõige 
rohkem on uuritud valku E2. E2 valk on väga oluline viiruse elutsükli reguleerija. Tema 
funktsiooniks on viiruse replikatsiooni initsieerimine, transkriptsiooni reguleerimine. Samuti 
on E2 vajalik viiruse genoomi tütarrakkude vahel jagamiseks, püsiva infektsiooni 
tekkimiseks.’ 
Esimene töö osa annab teoreetilise ülevaate inimese papilloomiviiruse elutsüklist ja genoomi 
ülesehitusest, fokusseerudes E2 valgu funktsioonidele. 
HPV18 E2 valgud ekspresseeruvad väga madala tasemel ja mõnikord on neid raske 
detekteerida, kasutades Western blot-i analüüsi. Antud töö eesmärgiks oli E2 koodon 
optimiseeritud järjestuse pCMV-Flag-4 vektorisse kloneerimine edasise ekspressioni taseme 
kontrollimisega ja bioloogilise aktiivsusega testimisega. 
Antud bakalaureuse töö on valminud Tartu Ülikooli Tehnoloogiainstituudis papilloomiviiruse 
uurimisrühmas. 
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